Table 1 Characteristics of included studies

Pujade-Lauraine 2010 [13]

carbo(AUC5) + PLD 30 mg/m2 q4wks

466

60.5 (24–82)

phase III randomized multicenter, open-label trial

PS ROC

After first-or second-line

Platinum and taxane-based

PFS, OS,

Toxicity

carbo(AUC5) + PAC 175 mg/m2 q3wks

509

61 (27–82)

Gladieff2012 [14]

carbo(AUC5) + PLD 30 mg/m2 q4wks

161

60 (24–82)

phase III randomized non-inferiority trial

PS ROC

After first- or second-line platinum- and taxane-based

PFS,

Toxicity

carbo(AUC5) + PAC 175 mg/m2 q3wks

183

60 (30–80)

Mahner2014 [15]

carbo(AUC5) + PLD 30 mg/m2 q4wks

131

60 (30–80)

phase III randomized multicenter trial

PS ROC

Platinum and

taxane-pretreated

PFS, OS,

Toxicity

carbo(AUC5) + PAC 175 mg/m2 q3wks

128

63 (27–82)

Bafaloukos2010 [16]

carbo(AUC5) + PLD 45 mg/m2 q4wks

93

62 (38–89)

phase II randomized

multicenter

PS ROC

One cycle or more

Of platinum-based

ORR, OS,

Toxicity

carbo(AUC5) + PAC 175 mg/m2 q3wks

96

63 (37–81)

Mutch2007 [17]

PLD 50 mg/m2 IVI q4wks

96

62 (28–83)

phase III randomized multicenter open-label

PS ROC

Prior platinum-based

≤ 2 prior regimens allowed

PFS, OS,

Toxicity

Gemcitabine 1000 mg/m2 D1,8 q3wks

99

59 (38–85)

Ferrandina2008 [18]

PLD 40 mg/m2 IVI q4wks

76

63 (28–80)

phase III randomized

multicenter

Partial PS and

PR ROC

Failed first-line

Platinum or paclitaxel

OS,

Toxicity

Gemcitabine 1000 mg/m2 D1,5,8,15 q4wks

77

63 (39–79)

Vergote2009I [19]

PLD 50 mg/m2 IVI q4wks

130

60 (30–82)

phase III randomized multicenter

platinum-refractory or PR ROC

Failed one second-Line therapy with either topotecan or PLD

Toxicity

Canfosfamide 1000 mg/m2 q3wks

231

60 (26–85)

Vergote2009II [19]

PLD 50 mg/m2 IVI q4wks

130

60 (30–82)

phase III randomized

multicenter

platinum-refractory or PR ROC

Failed one second-Line therapy with either topotecan or PLD

Toxicity

Topotecan 1.5 mg/m2 D1–5 q3wks

87

60 (30–82)

Colombo2012 [20]

PLD 50 mg/m2 IVI q4wks

417

59 (23–84)

phase III randomized

open-label

PR ROC

Failed≥4 cycles of platinum-based or discontinued

PFS, OS,

Toxicity

Patupilone 10 mg/m2 IVI q3wks

412

59 (25–87)

Banerjee2018 [21]

PLD 40 mg/m2 IVI q4wks

48

62 (52–86)

phase II randomized

open-label

PR ROC

Progressed or relapsed < 6 months with a platinum-based

PFS,

Toxicity

LIFA 2.4 mg/kg q3wks

47

62 (43–83)

Kaye2012I [22]

PLD 50 mg/m2 IVI q4wks

33

53 (43–81)

phase II open-label randomized Multicenter

Partial PS and PR ROC

Recurred or progressed < 12

months with platinum-based

PFS, OS,

Toxicity

Olaparib 200 mg bid continuously

32

58.5 (45–77)

Kaye2012II [22]

PLD 50 mg/m2 IVI q4wks

33

53 (43–81)

phase II open-label randomized Multicenter

Partial PS and

PR ROC

Recurred or progressed < 12

months with platinum-based

PFS,OS,

Toxicity

Olaparib 400 mg bid continuously

32

53.5 (35–76)